New targeted cancer drug enters Mid-Stage testing
NCT ID NCT07202364
Summary
This study is testing an experimental drug called YL202 in people with advanced solid tumors, including lung, colorectal, and cervical cancer, that have spread or cannot be removed by surgery. The goal is to see if the drug can shrink tumors and control the disease, and to understand its safety. It is for adults who have already tried 1 or 2 other treatments for their advanced cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hunan Provincial Tumor Hospital
RECRUITINGChangsha, Hunan, 410006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.